Investor Presentation First Nine Months of 2022

133 Investor presentation First nine months of 2022 North America Operations growth has accelerated DKK billion 3% North America Operations reported sales growth per therapy area 1% 60 60 57 3% 61 14% 22% 67 64 2018 GLP-1 2019 Insulin Other diabetes 2020 Obesity care 2021 9M 2022 Rare disease Growth at CER CER: Constant exchange rate; 9M: 9 months Source: Quarterly company announcement NAO

View entire presentation